Krensavage Asset Management, LLC Buys Exelixis Inc, Eagle Pharmaceuticals Inc, Sells AnaptysBio Inc

New York, NY, based Investment company

Krensavage Asset Management, LLC (Current Portfolio) buys Exelixis Inc, Eagle Pharmaceuticals Inc, sells AnaptysBio Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Krensavage Asset Management, LLC. As of 2021Q3, Krensavage Asset Management, LLC owns 13 stocks with a total value of $319 million. These are the details of the buys and sells.

• New Purchases: EXEL,
• Added Positions: EGRX, BIIB,
• Reduced Positions: ALKS, REGN, UTHR, MCK, IVC, SRGA, TVTX, NXTC,
• Sold Out: ANAB,

For the details of Krensavage Asset Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/krensavage+asset+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Krensavage Asset Management, LLC

1. Enanta Pharmaceuticals Inc (ENTA) - 936,777 shares, 16.69% of the total portfolio. Shares reduced by 0.31%
2. Alkermes PLC (ALKS) - 1,441,967 shares, 13.95% of the total portfolio. Shares reduced by 14.62%
3. Regeneron Pharmaceuticals Inc (REGN) - 73,143 shares, 13.89% of the total portfolio. Shares reduced by 10.91%
4. United Therapeutics Corp (UTHR) - 207,287 shares, 12.00% of the total portfolio. Shares reduced by 5.65%
5. Taro Pharmaceutical Industries Ltd (TARO) - 545,583 shares, 10.89% of the total portfolio. Shares added by 0.35%

New Purchase: Exelixis Inc (EXEL)

Krensavage Asset Management, LLC initiated holding in Exelixis Inc. The purchase prices were between $16.3 and $21.14, with an estimated average price of $18.58. The stock is now traded at around $17.860000. The impact to a portfolio due to this purchase was 6.63%. The holding were 1,000,000 shares as of 2021-09-30.

Added: Eagle Pharmaceuticals Inc (EGRX)

Krensavage Asset Management, LLC added to a holding in Eagle Pharmaceuticals Inc by 52.21%. The purchase prices were between $43.79 and $55.78, with an estimated average price of $49.16. The stock is now traded at around $51.750000. The impact to a portfolio due to this purchase was 0.65%. The holding were 107,773 shares as of 2021-09-30.

Sold Out: AnaptysBio Inc (ANAB)

Krensavage Asset Management, LLC sold out a holding in AnaptysBio Inc. The sale prices were between $22.98 and $28.1, with an estimated average price of $25.41.

Here is the complete portfolio of Krensavage Asset Management, LLC. Also check out:

1. Krensavage Asset Management, LLC's Undervalued Stocks
2. Krensavage Asset Management, LLC's Top Growth Companies, and
3. Krensavage Asset Management, LLC's High Yield stocks
4. Stocks that Krensavage Asset Management, LLC keeps buying